(IN BRIEF) Team ULTRATOPIA from KU Leuven and Balgrist University Hospital has won the KUKA Innovation Award 2025 for a medical-robotics solution that uses ultrasound-guided collaborative robots to increase the accuracy and safety of pedicle screw placement during spinal surgery. … Read the full press release
Posted in Awards, Business, Electronics & Machinery, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Technology
Tagged Axel Weber, Balgrist University Hospital, collaborative robots, EU-funded research, FAROS project, healthcare robotics, KU Leuven, KUKA Innovation Award 2025, MEDICA trade fair, medical robotics, non radiative imaging, pedicle screw placement, precision surgery, robotic spinal surgery, Surgical Innovation, ultrasound guided surgery, ULTRATOPIA, ULTRATOPIA Researchers Develop Advanced Dual-Robot Ultrasound Method for Precision Spine Procedures, University of Zurich
(IN BRIEF) Novonesis has teamed up with thyssenkrupp Uhde to launch a revolutionary enzymatic fat-splitting process using the Lipura® Split enzyme, replacing traditional high-pressure thermal methods. By leveraging biosolutions at lower temperatures and atmospheric pressure, this method reduces energy and … Read the full press release
Posted in Business, Chemicals, Denmark, Germany, Industrial, News, Pharma & Biotech, Science, Technology
Tagged biosolutions, CAPEX reduction, energy efficiency, enzymatic fat-splitting, fatty acid production, Green Chemistry, Hans Ole Klingenberg, Lipura Split enzyme, Nadja Håkansson, Novonesis, oleochemical industry, pilot plant, process flexibility, Strategic Partnership Introduces Scalable, Sustainable Fat-Splitting Solution for Oleochemical Producers, sustainable manufacturing, ThyssenKrupp Uhde
(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease. Developed by Polpharma Biologics, TYRUKO® is clinically equivalent to its reference product and … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged affordable biologics, biosimilar growth, Crohn's disease, FDA approval, JCV antibodies, Keren Haruvi, Labcorp partnership, multiple sclerosis, natalizumab-sztn, neurology portfolio, PML risk, Polpharma Biologics, REMS program, Sandoz, TYRUKO, TYRUKO Availability Marks Major Milestone in Affordable MS Care and Sandoz Biosimilar Leadership, Tysabri biosimilar, US launch
(IN BRIEF) At COMPAMED 2025, WACKER introduces several groundbreaking silicone solutions aimed at redefining medical adhesive and tubing performance while advancing environmental goals. The main attraction is SILPURAN® eco 2114, a biomethanol-based silicone gel adhesive produced under mass balance certification … Read the full press release
Posted in Business, Chemicals, Germany, Industrial, Marketing, News, Pharma & Biotech, Science, Technology
Tagged biomethanol silicone adhesive, carbon footprint reduction, COMPAMED 2025, Dr Ufuk Karabiyik, Düsseldorf, ELASTOSIL R plus 4360, ELASTOSIL R plus 4366, Healthcare Innovation, Ian Moore, Innovative Silicone Adhesives and Tubing Solutions Highlight WACKER’s COMPAMED 2025 Showcase, low-friction surface, medical technology, medical tubing, peristaltic pumps, REDcert2, silicone gel, SILPURAN eco 2114, sustainability, transdermal patches, WACKER
(IN BRIEF) The German Research Center for Artificial Intelligence (DFKI) and Mainz University Medical Center have initiated the MARK project to understand and predict the biological aging of the immune system using artificial intelligence. Funded by the Rhineland-Palatinate Ministry of … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Environment, Germany, Healthcare, News, Pharma & Biotech, Science, Society, Technology
Tagged aging research, AI in medicine, Andreas Dengel, artificial intelligence, biotechnology, blood stem cells, Center for Thrombosis and Hemostasis, Clemens Hoch, data science, DFKI, DFKI and Mainz researchers pioneer AI-driven insights into immune decline and age-related health risks, Germany, healthy aging, immune system aging, Kaiserslautern, life sciences, Mainz, Mainz University Medical Center, MARK project, MARK project combines artificial intelligence and biotechnology to advance healthy aging research in Rhineland-Palatinate, Molecular Analysis of Age-Related Risk Mechanisms, predictive health models, Rhineland-Palatinate Ministry of Science and Health, Wolfram Ruf
(IN BRIEF) ETH Zurich scientists have developed a novel iron supplement using oat protein nanofibrils coated with iron nanoparticles, offering nearly twice the absorption rate of standard iron sulphate supplements. The plant-based formula is vegan-friendly, tasteless, and easy to incorporate … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged anaemia, bioavailability, clinical study, dietary supplement, ETH Zurich, ETH Zurich researchers create breakthrough iron supplement with nearly double absorption efficiency, global health, iron deficiency, iron nanoparticles, Jiangtao Zhou, Michael B. Zimmermann, National University of Singapore, Nature Food, Nutrition, oat protein nanofibrils, Raffaele Mezzenga, selenium deficiency, sustainable nutrition, THAILAND, vegan supplement, zinc deficiency
(IN BRIEF) A major review led by the University of Liverpool and published in The BMJ finds no reliable evidence linking paracetamol use during pregnancy with autism or ADHD in children. Evaluating nine systematic reviews comprising 40 studies, researchers determined … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acetaminophen, ADHD, autism, Liverpool researchers find weak evidence behind claims linking paracetamol in pregnancy to child neurodevelopmental disorders, Louise Kenny, maternal health, medical research, medication safety, neurodevelopment, paracetamol, pregnancy, public health, Shakila Thangaratinam, The BMJ, UK science, University of Liverpool, Women’s Health
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amgen Pharmaceuticals, cancer research, clinical trial, Dr Lucy Bull Foundation, ICR, ILP, immunotherapy, isolated limb perfusion, Journal for ImmunoTherapy of Cancer, London, Mabs Mardulyn Charitable Foundation, melanoma, NIHR Biomedical Research Centre, oncolytic virus, Professor Alan Melcher, Professor Andrew Hayes, Robert McAlpine Foundation, Royal Marsden Melanoma and Sarcoma Research Fund, sarcoma, Sarcoma UK, T-VEC, talimogene laherparepvec, The Institute of Cancer Research, The Institute of Cancer Research pioneers new dual treatment combining virus therapy and isolated limb perfusion to enhance immune response in advanced cancer, The Royal Marsden NHS Foundation Trust, tumour immunity, United Kingdom, virotherapy
(IN BRIEF) Boehringer Ingelheim and CDR-Life have expanded their partnership through a global licensing agreement to develop CDR111, a trispecific M-gager® antibody designed to reset the immune system by selectively targeting B cells. The collaboration builds upon their prior success … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antibody-based therapy, Arthritis, autoimmune diseases, B cells, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim and CDR-Life Expand Partnership with New Global Licensing Deal to Advance Autoimmune Disease Therapies, Carine Boustany, CDR-Life, CDR111, Christian Leisner, Geographic Atrophy, global licensing agreement, immune system reset, lupus, multiple sclerosis, pharmaceutical collaboration, T-cell engager, trispecific M-gager, USD 570 million deal, VERDANT Phase 2 trial
(IN BRIEF) The European Investment Bank (EIB) has provided a €20 million loan to Overture Life to develop automated and AI-driven technologies for in vitro fertilization (IVF) and egg freezing. The funding supports the company’s R&D, production expansion, and clinical … Read the full press release
Posted in Artificial Intelligence (AI), Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Science, Spain, Technology
Tagged AI in healthcare, Bio-Europe 2025, biotechnology, DaVitri platform, EIB, EIB Backs Overture Life’s Innovation to Make IVF More Efficient and Widely Available through AI, EIB Invests €20 Million in Overture Life to Advance AI-Based Fertility and IVF Technologies, European Innovation, European Investment Bank, fertility preservation, fertility technology, Hans Gangeskar, healthcare digitalisation, innovation funding, InvestEU, IVF automation, Karl Nehammer, life sciences, Overture Life, reproductive health, TechEU, Vienna, Women’s Health
(IN BRIEF) The European Medicines Agency (EMA), together with leading European healthcare professional and consumer organisations, has launched the #ItTakesATeam campaign to raise awareness of collective efforts in preventing and managing medicine shortages across the EU. The initiative, co-created with … Read the full press release
Posted in Healthcare, Management, Marketing, Media, News, Pharma & Biotech, United Kingdom
Tagged #ItTakesATeam, awareness campaign, EMA, EMA Unites European Healthcare Partners in #ItTakesATeam Campaign to Tackle Medicine Shortages, Emer Cooke, EU healthcare collaboration, European Association of Hospital Pharmacists, European Association of Nuclear Medicine, European Consumer Organisation, European Medicines Agency, European Paediatric Neurology Society, European Union of General Practitioners, healthcare professionals, Jorge Batista, medicine shortages, medicine supply chain, New EMA Awareness Initiative Highlights Collaborative Efforts Behind Managing Medicine Shortages Across Europe, patient safety, PGEU, public health, regulatory cooperation
(IN BRIEF) Boehringer Ingelheim has licensed a pre-clinical small molecule program from Kyowa Kirin to develop a potential first-in-class therapy for autoimmune diseases, a major global health challenge affecting around 10% of the population. The deal grants Boehringer exclusive worldwide … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged autoimmune diseases, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim Secures Exclusive Global Rights to Develop New Autoimmune Treatment from Kyowa Kirin, Boehringer Ingelheim Strengthens Autoimmune Disease Pipeline with Licensing Agreement from Kyowa Kirin, Carine Boustany, chronic inflammation, drug development, global health, immunology, inflammatory diseases, Kyowa Kirin, licensing agreement, pharmaceutical innovation, pre-clinical program, respiratory diseases, small molecule therapy, Takeyoshi Yamashita
(IN BRIEF) Causeway Therapeutics, a University of Glasgow spin-out, has announced strong Phase 2 results for its novel microRNA therapy, TenoMiR®, used to treat tennis elbow. The study, involving 123 patients across the UK and USA, showed significant improvements in … Read the full press release
Posted in Education, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biotechnology, Causeway Therapeutics, Causeway Therapeutics Advances TenoMiR® Development Following Strong Phase 2 Results, clinical research, Declan Doogan, Derek Gilchrist, Glasgow City Council, Glasgow Riverside Innovation District, Iain McInnes, lateral epicondylitis, microRNA therapy, miR29a, Neal Millar, orthopaedic innovation, phase 2 trial, Phase 3 development, Promising Clinical Data Propel Glasgow Biotech Causeway Therapeutics Toward Full Development of TenoMiR®, Scott Rodeo, Scottish Enterprise, tendinopathy, tendon regeneration, tennis elbow, TenoMiR, University of Glasgow
Pertussis cases surge: Over 60,000 reported in Europe; infants most at risk. Maternal vaccination expands: Finland, Norway, and UK updated pregnancy vaccine strategies. BioNet advances: Submitted recombinant pertussis vaccine to EMA; secured EU-GMP approval. Nasal vaccine progresses: ILiAD’s BPZE1 granted … Read the full press release
Posted in Denmark, European Union, Finland, France, Germany, Healthcare, Ireland, News, Norway, Pharma & Biotech, Science, United Kingdom
Tagged acellular pertussis vaccine, Adacel, antibody avidity, antigen dose, ASEAN, Bio Farma, BioNet, biotechnology, booster dose, Boostrix-IPV, BPZE1, certification, Chulalongkorn University, clinical trial, compliance, Dario Cresci, dTap, ECDC, EMA, EU-GMP, EU-GMP certification, EU/EEA, Europe Confronts Pertussis Resurgence as Infant Cases Rise Amid Falling Immunity and Vaccination Gaps, Europe Faces Pertussis Resurgence Amid Waning Immunity and Falling Maternal Vaccination Rates, European Medicines Agency, European Union, European Union Good Manufacturing Practice, Europe’s Pertussis Vaccine Market Opens to New Entrants as Demand Rises, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, GSK, Hanna Nohynek, health policy, HPRA, human challenge trial, hVIVO, ILiAD Biotechnologies, immunization strategy, infant protection, Innovation Passport, Institut Pasteur, intranasal vaccine, Ireland Health Products Regulatory Authority, Lancet Infectious Diseases, maternal vaccination, MHRA, mucosal immunity, outbreak, pandemic recovery, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Phase 3, Philippe Guillot-Chêne, pregnancy immunization, public health, recombinant pertussis vaccine, recombinant pertussis vaccines, regulatory approval, Sanofi, Tdap, TdaP combination vaccine, V, vaccine, vaccine blunting, vaccine development, Vaccine Hesitancy, vaccine pipeline, vaccine rollout, vaccine shortage, vaccine supply, vaccine uptake, VacPertagen, whooping cough
(IN BRIEF) Fresenius Medical Care will present multiple studies at ASN Kidney Week 2025, highlighting how hemodiafiltration (HDF) enhances clinical outcomes and how artificial intelligence is transforming kidney care. One of the featured oral presentations links HDF to a reduced … Read the full press release
Posted in Artificial Intelligence (AI), Business, Germany, Healthcare, Marketing, Pharma & Biotech, Science, Technology
Tagged AI Chatbot, AI in healthcare, ASN Kidney Week 2025, cardiovascular outcomes, clinical research, dialysis, digital innovation, Frank Maddux, Fresenius Medical Care, Fresenius Medical Care Highlights Real-World Benefits of Hemodiafiltration and AI Innovation at ASN Kidney Week in Houston, HDF, hemodiafiltration, HOUSTON, kidney disease, kidney therapy, nephrology, online high-volume HDF, patient care, precision medicine, Renal Research Institute
(IN BRIEF) Brenntag has signed an exclusive European distribution agreement with ArcticZymes AS for its line of salt-active nucleases—SAN HQ, SAN-HQ GMP, M-SAN HQ, and M-SAN HQ GMP—used in gene therapy, vaccine manufacturing, and bioprocessing. Signed during the CPHI fair … Read the full press release
Posted in Business, Chemicals, Financial, Germany, Industrial, Management, Pharma & Biotech
Tagged ArcticZymes, biopharma, biopharmaceutical innovation, bioprocessing, biotechnology, Brenntag, Brenntag and ArcticZymes Join Forces to Support Growth in Biopharmaceutical and Gene Therapy Markets, CPHI Frankfurt, downstream processing, enzyme distribution, enzymes, European partnership, gene therapy, GMP, Joakim Rehné, life sciences, M-SAN HQ, nucleases, Paul Blackburn, SAN HQ, vaccine manufacturing
BioNet earns EU-GMP certification for its acellular pertussis vaccine, confirming compliance with EU manufacturing and quality standards. Inspection by Ireland’s HPRA supports EMA review of BioNet’s recombinant vaccine candidate VacPertagen. Partnerships expanding: MoU with Indonesia’s Bio Farma to accelerate TdaP … Read the full press release
Posted in European Union, France, Healthcare, Ireland, Pharma & Biotech, Science
Tagged acellular pertussis vaccine, BioNet, BioNet’s EU-GMP Certification Marks Strategic Step Toward EMA Review and Expands Global Vaccine Reach, BioNet’s Manufacturing Accreditation Aligns with Growing International Efforts to Reinforce Pertussis Vaccine Supply, biotechnology, certification, compliance, Dario Cresci, EMA, EU-GMP certification, European Medicines Agency, European Union, European Union Good Manufacturing Practice, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, HPRA, Ireland Health Products Regulatory Authority, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Philippe Guillot-Chêne, recombinant pertussis vaccines, Regulatory Milestone and Research Progress Signal BioNet’s Expanding Role in Next-Generation Vaccine Development, V, vaccine, VacPertagen
(IN BRIEF) AstraZeneca’s Alexion has secured European Commission approval for Koselugo (selumetinib), the first targeted therapy available to adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The approval is based on the KOMET Phase III trial, … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 treatment, Alexion, American Society of Clinical Oncology, APHP, ASCO 2025, AstraZeneca, AstraZeneca Expands Rare Disease Portfolio with EU Approval of Koselugo for Adults with NF1 Tumours, European Commission approval, European Union, Henri Mondor Hospital, Japan approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, Paris East University, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease therapy, selumetinib, The Lancet, tumour response rate, UPEC
(IN BRIEF) BioNet has achieved European Union Good Manufacturing Practice (EU-GMP) certification, a key international standard that validates its facilities and processes for producing high-quality pharmaceuticals. This certification, granted after inspection by Ireland’s Health Products Regulatory Authority (HPRA), allows BioNet … Read the full press release
Posted in European Union, France, Healthcare, Ireland, Pharma & Biotech
Tagged acellular pertussis vaccine, BioNet, biotechnology, certification, compliance, Dario Cresci, EMA, EU-GMP certification, European Medicines Agency, European Union, European Union Good Manufacturing Practice, GMP production facilities, HPRA, Ireland Health Products Regulatory Authority, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Philippe Guillot-Chêne, recombinant pertussis vaccines, vaccine, VacPertagen
(IN BRIEF) GSK announced that its B7-H3-targeted antibody-drug conjugate GSK5764227 (GSK’227) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer (SCLC). The designation is supported … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, cancer research, EMA, EMA Grants Orphan Drug Designation to GSK’s B7-H3 Antibody-Drug Conjugate for Pulmonary Neuroendocrine Carcinoma, FDA, GSK, GSK Strengthens Oncology Pipeline With EMA Orphan Drug Status for GSK’227 in Small-Cell Lung Cancer, GSK5764227, GSK’227, immuno-oncology, lung cancer, NEC, ODD, oncology, oncology pipeline, orphan drug designation, PRIME designation, pulmonary neuroendocrine carcinoma, relapsed or refractory, SCLC, Small cell lung cancer, solid tumours, targeted therapy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?